TABLE 1.
Population characteristics and biological results.
| Population | n = 120 |
| Age (years)* | 64.6 ± 13.89 |
| Sex–no (%) | |
| Female | 79 (65.8) |
| Male | 41 (34.2) |
| Symptomatic–no (%) | 61 (50.8) |
| Ectopic–no (%) | 17 (14.3) |
| Primary hyperparathyroidism–no (%) | 100 (83.3) |
| Secondary or tertiary hyperparathyroidism–no (%) | 20 (16.7) |
| Pre-surgery characteristics* | |
| Size (mm) | 10.28 ± 5.43 |
| Serum calcium (mmol/L) | 2.78 ± 0.33 |
| Serum PTH (pmol/L) | 127.19 ± 85.05 |
| [18F]fluorocholine (MBq) | 218.27 ± 56.03 |
| CTDI (mGy) | 14.82 ± 10.31 |
| PDL (mGy.cm) | 566.52 ± 301.15 |
| Post-surgery characteristics* | n = 96 |
| Serum PTH (pmol/L) | 23.11 ± 29.79 |
| Variation** PTH (pmol/L) | 92.65 ± 67.05 |
*Mean ± SD (range).
**Variation between pre- and post-surgery serum PTH level.
Serum calcium standards at the Lyon laboratory: 2.04–2.39 mmol/L.
Serum calcium standards at the Saint Etienne laboratory: 2.1–2.55 mmol/L.
Serum PTH level standards at the Lyon laboratory: 15–57 ng/L.
Serum PTH level standards at the Saint Etienne laboratory: 5.5–38.4 ng/L.
Serum calcium levels are corrected to albumin or protide concentration.
CTDI, computed tomography dose index; DLP, dose length product; PTH, parathyroid hormone; SUVmax, maximum standardized uptake value.